124 related articles for article (PubMed ID: 8995350)
1. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer).
Pecking AP; Février B; Wargon C; Pillion G
Angiology; 1997 Jan; 48(1):93-8. PubMed ID: 8995350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Guilhou JJ; Dereure O; Marzin L; Ouvry P; Zuccarelli F; Debure C; Van Landuyt H; Gillet-Terver MN; Guillot B; Levesque H; Mignot J; Pillion G; Février B; Dubeaux D
Angiology; 1997 Jan; 48(1):77-85. PubMed ID: 8995348
[TBL] [Abstract][Full Text] [Related]
3. Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.
Pecking AP
Int Angiol; 1995 Sep; 14(3 Suppl 1):39-43. PubMed ID: 8919264
[TBL] [Abstract][Full Text] [Related]
4. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial.
Guilhou JJ; Février F; Debure C; Dubeaux D; Gillet-Terver MN; Guillot B; Levesque H; Marzin L; Mignot J; Ouvry P; Pillion G; Van Landuyt H; Zuccarelli F; Nicolaïdes AN
Int J Microcirc Clin Exp; 1997; 17 Suppl 1():21-6. PubMed ID: 9477041
[TBL] [Abstract][Full Text] [Related]
5. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
Amato C
Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Olszewski W
Angiology; 2000 Jan; 51(1):25-9. PubMed ID: 10667640
[TBL] [Abstract][Full Text] [Related]
7. [Hemorrhoids and conservative treatment. Review of the literature on the use of diosmin and micronized hesperidin].
La Torre F; Nicolai AP; Otti M
Minerva Chir; 1999 Dec; 54(12):909-16. PubMed ID: 10736998
[No Abstract] [Full Text] [Related]
8. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency.
Belcaro G; Cesarone MR; de Sanctis MT; Incandela L; Laurora G; Février B; Wargon C; De Gregoris P
Int J Microcirc Clin Exp; 1995; 15 Suppl 1():45-9. PubMed ID: 8748889
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study.
Cluzan RV; Pecking AP; Mathiex-Fortunet H; Léger Picherit E
Lymphology; 2004 Jun; 37(2):47-52. PubMed ID: 15328756
[TBL] [Abstract][Full Text] [Related]
10. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Geroulakos G; Nicolaides AN
Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
[TBL] [Abstract][Full Text] [Related]
11. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Godeberge P
Angiology; 1994 Jun; 45(6 Pt 2):574-8. PubMed ID: 8203790
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Cospite M
Angiology; 1994 Jun; 45(6 Pt 2):566-73. PubMed ID: 8203789
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy.
Ho YH; Foo CL; Seow-Choen F; Goh HS
Br J Surg; 1995 Aug; 82(8):1034-5. PubMed ID: 7648143
[TBL] [Abstract][Full Text] [Related]
14. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency.
Allegra C; Bartolo M; Carioti B; Cassiani D
Int J Microcirc Clin Exp; 1995; 15 Suppl 1():50-4. PubMed ID: 8748890
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
Galley P; Thiollet M
Int Angiol; 1993 Mar; 12(1):69-72. PubMed ID: 8376915
[TBL] [Abstract][Full Text] [Related]
16. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Meyer OC
Angiology; 1994 Jun; 45(6 Pt 2):579-84. PubMed ID: 8203791
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
Hnátek L
Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
[TBL] [Abstract][Full Text] [Related]
18. [Lymphedema secondary to breast cancer treatment: possibility of diagnostic and therapeutic prevention].
Campisi C; Boccardo F; Zilli A; Maccio A; Napoli F; Ferreira Azevedo W; Fulcheri E; Taddei G
Ann Ital Chir; 2002; 73(5):493-8. PubMed ID: 12704989
[TBL] [Abstract][Full Text] [Related]
19. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
Struckmann JR; Nicolaides AN
Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
[TBL] [Abstract][Full Text] [Related]
20. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Gothard L; Cornes P; Earl J; Hall E; MacLaren J; Mortimer P; Peacock J; Peckitt C; Woods M; Yarnold J
Radiother Oncol; 2004 Nov; 73(2):133-9. PubMed ID: 15542159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
